
Curis (CRIS) Stock Forecast & Price Target
Curis (CRIS) Analyst Ratings
Bulls say
Curis is currently showing promising results in their clinical trials for their drugs targeting primary CNS lymphoma, with a 26% ORR on an all-patients basis and a 33% ORR in evaluable patients. Their pipeline expansion to include all five NHL subtypes and their successful enrollment in the TakeAim CLL study suggest strong potential for future growth and success. Additionally, the company's deep responses and undetectable minimal residual disease when combining emavusertib with a BTK inhibitor provide further evidence of the potential of their drugs.
Bears say
Curis is facing challenges due to the low success rate of its pipeline products, as seen in the BTKi-experienced and BTKi-naïve groups where response rates are relatively low. The company's financial update also shows a lack of profitability, with a negative EPS and small cash reserves. Additionally, the expanded TakeAim CLL readout has been delayed and the company is still in its early stages of clinical trials, making it a risky investment for potential investors.
This aggregate rating is based on analysts' research of Curis and is not a guaranteed prediction by Public.com or investment advice.
Curis (CRIS) Analyst Forecast & Price Prediction
Start investing in Curis (CRIS)
Order type
Buy in
Order amount
Est. shares
0 shares